文献速递甲状腺核医学核素与放射性配体治疗

甲状腺微小乳头状癌微小腺外侵犯是淋巴结及远处转移复发的独立危险因素

Minimal Extrathyroidal Extension in Papillary Thyroid Microcarcinoma Is an Independent Risk Factor for Relapse Through Lymph Node and Distant Metastases.
PubMed 文献 · J Nucl Med · 2021-12-01

该回顾性分析纳入721例甲状腺微小乳头状癌(PTMC)患者,中位随访9.30年,评估微小腺外侵犯(mETE)与淋巴结转移及复发的关系。结果显示mETE是甲状腺切除术时淋巴结转移的独立危险因素(调整OR 4.33,95%CI 2.02-9.60,P<0.001),且与淋巴结复发(5年13.1% vs 1.25%,P<0.001)和远处转移(5年7.8% vs 1.1%,P<0.001)显著相关。

要点

  • mETE是PTMC患者甲状腺切除术时淋巴结转移的独立危险因素(调整OR 4.33)。
  • mETE患者5年淋巴结复发率13.1%,无mETE者仅1.25%(P<0.001)。
  • mETE患者5年远处转移率7.8%,无mETE者1.1%(P<0.001)。

核心结论

  • mETE是PTMC患者经淋巴结和远处转移复发的独立危险因素。

研究设计与样本

  • 回顾性分析纳入1983年5月至2012年8月术后咨询的721例PTMC患者,中位随访9.30年。

主要发现

  • 10.7%(77例)患者存在mETE,多变量分析中mETE是甲状腺切除术时淋巴结转移的独立危险因素(调整OR 4.33,95%CI 2.02-9.60,P<0.001)。
  • mETE患者5年淋巴结复发率13.1%,显著高于无mETE者的1.25%(P<0.001)。
  • mETE患者5年远处转移率7.8%,显著高于无mETE者的1.1%(P<0.001)。
  • 多变量分析中mETE是淋巴结复发(HR 7.78,95%CI 2.87-21.16,P<0.001)和远处转移(HR 4.09,95%CI 1.25-13.36,P=0.020)的独立危险因素。

临床怎么用

  • 对于PTMC伴mETE患者,应考虑加强监测并评估强化治疗的必要性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Minimal extrathyroidal extension (mETE) of papillary thyroid microcarcinoma (PTMC) is no longer considered in the new eighth edition of the staging manual of the American Joint Committee on Cancer and the International Union Against Cancer. Therefore, PTMC with mETE previously staged as pT3 will now be staged as pT1a and most likely not receive adjuvant radioiodine therapy. However, it remains unclear whether mETE is associated with higher aggressiveness in PTMC. Therefore, the aim of this study was to investigate whether mETE is associated with a higher risk of lymph node metastases (LNMs) or distant metastases. Methods: In total, 721 patients with PTMC presenting at our department for postoperative counseling from May 1983 to August 2012 were included in this retrospective analysis (median follow-up time, 9.30 y). The impact of mETE on the presence of LNMs at thyroidectomy and relapse through LNMs and distant metastases was assessed by logistic regression and Fine-Gray model analyses. Results: mETE was present in 10.7% (n = 77) of patients and was an independent risk factor for LNMs at thyroidectomy, with an adjusted odds ratio of 4.33 (95% CI, 2.02-9.60; P < 0.001) in multivariable analysis. Patients with mETE had significantly more relapses through LNMs (over 5 y: 13.1% vs. 1.25%; P < 0.001) and distant metastases (over 5 y: 7.8% vs. 1.1%; P < 0.001) than did patients without mETE. mETE was an independent risk factor for relapse through LNMs and distant metastases in multivariable analysis (hazard ratio of 7.78 and 95% CI of 2.87-21.16 for LNMs [P < 0.001]; hazard ratio of 4.09 and 95% CI of 1.25-13.36 for distant metastases [P = 0.020]). Conclusion: mETE is a statistically significant and independent risk factor for relapse through LNMs and distant metastases in PTMC. Therefore, future studies should evaluate whether patients with mETE and PTMC might benefit from intensified surveillance and therapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Seifert R, Schäfers M, Heitplatz B, et al. Minimal Extrathyroidal Extension in Papillary Thyroid Microcarcinoma Is an Independent Risk Factor for Relapse Through Lymph Node and Distant Metastases. J Nucl Med. 2021. PMID: 33771902. doi:10.2967/jnumed.121.261898

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。